Home Reagents Clinical Chemistry Reagents Amylase pancreatic (liquid) assay
Quality Guranteed Fast Delivery ad for support

Amylase pancreatic (liquid) assay

Product Method Size Catalog Price Quantity
Amylase pancreatic (liquid) assay EPS R1 6 x 20ml, R2 3 x 10ml AY7934 $660.68
Shipping costs will be added at the checkout stage, click here for charges.
  • Format
    Liquid ready to use
  • Assay Range
    6.11 - 1500U/L
  • Working Stability 15-25 °C
    _
  • Working Stability 2-8 °C
    Stable to expiry
Request Kit Insert

Intended Use

For the quantitative in vitro determination of pancreatic α-amylase in serum, plasma and urine. This product is suitable for use on the Hitachi 704, 717, 902, 911 and 912.


Clinical Significance


The amylases are a group of hydrolases that split complex carbohydrates constituted of ω-D-glucose units. The two recognized types of amylases are ß-amylase (e.g. plant and bacterial exoamylase) and human ω-amylases which can attack the ω-1, 4-linkage anywhere along a polyglucan chain. Human ω-amylase consists of two major isoenzymes, pancreatic and salivary, which are encoded by two different genes. Pancreatic amylase is synthesized only in pancreatic tissue by acinar cells, however the salivary amylase is found in numerous locations, such as salivary glands and female genital, pulmonary and malignant tissues.

Amylase measurements are used primarily for the diagnosis and treatment of pancreatitis (severe inflammation of the pancreas) as well as pancreatic diseases. Amylase levels rise quickly at the start of a pancreatitis attack and fall after around 2 days. Elevated levels may also be associated with cancer of the pancreas, a perforated ulcer, gallbladder disease, mumps or ectopic pregnancy.

Total amylase determinations used for the evaluation of pancreatic disorders often give misleading information due to the high concentrations of salivary amylase present. The evaluation of pancreatic isoamylase would have a greater clinical specificity for the diagnosis of pancreatic disorders than total amylase assessment. This double monoclonal antibody (immuno-inhibition) technique uses the synergistic action of two monoclonal antibodies. The antibodies will inhibit almost completely salivary amylase and therefore allow the measurement of pancreatic amylase.


Principle

Two monoclonal antibodies are incubated with the sample to inhibit the salivary amylase present but do not affect pancreatic amylase. This method uses ethylidene-p-nitrophenyl maltoheptaoside as the substrate. The substrate is then added and any amylase present splits the substrate to produce oligosaccharides and pNP-G2, pNP-G3 and pNP-G4. α-glucosidase is added as the indicator enzyme to release the p-nitrophenol (p-NP). The final result of the hydrolysis by amylase and α-glucosidase is free p-NP, which is detected by its absorbance at 405 nm. The terminal glucose is blocked preventing cleavage by the indicator enzyme.


Available Applications

  • Abbott Architect + Aeroset
  • Alcyon 300 + Falcor
  • BT2000/BT3000/ILAB300/TARGA
  • ILAB1800, 900, 600
  • Clinline, Lisa Series + Mascott Plus
  • Cobas Mira, Mira S + Mira Plus, Fara, Bio
  • Express 550
  • Hitachi 704, 717, 902, 911, 912, 917
  • Konelab 20i, 30i + 60i
  • Olympus AU2700, 400, 600, 560
  • Ortho Fusion
  • Synchron CX 4, CX 5, CX 7, CX 9, LX20
  • Vitalab Flexor, Selectra E + Selectra II